Drug Interaction Report
1 drug interaction and 6 additional warnings found for the following 2 drugs:
- trofinetide
- ziftomenib
Drug interactions
Moderate drug interactions
Moderate:trofinetide ziftomenib
Applies to: trofinetide, ziftomenib
Trofinetide may increase the blood levels of ziftomenib. High levels of ziftomenib can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening.
You may be more susceptible if you have:
- a heart condition called congenital long QT syndrome
- other cardiac diseases
- conduction abnormalities
- electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting)
Increased levels of ziftomenib may also increase the risk of developing a serious and potentially life-threatening condition called differentiation syndrome. Symptoms of differentiation syndrome include:
- fever
- cough
- shortness of breath
- severe headache
- confusion
- dizziness
- rapid weight gain
- swelling
- decreased urination
You should seek immediate medical attention if you develop any of these symptoms and/or symptoms of QT prolongation such as sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with ziftomenib.
The risk and/or severity of other side effects may also increase, including nausea, vomiting, diarrhea, fever or infections.
Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need more frequent monitoring to safely use both medications.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:Food/Lifestyle ziftomenib
Applies to: ziftomenib
High-fat content meals may significantly increase the blood level and effects of ziftomenib. It is recommended that ziftomenib be taken on an empty stomach, at least 1 hour before or 2 hours after a meal.
Grapefruit juice may also increase the blood levels of ziftomenib, which can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting).
Increased levels of ziftomenib may also increase the risk of developing a serious and potentially life-threatening condition called differentiation syndrome. Symptoms of differentiation syndrome include:
- fever
- joint or bone pain
- dizziness
- shortness of breath or difficulty breathing
- cough
- chest pain
- rapid weight gain and/or swelling
- rash
- decreased urinary output
You should seek immediate medical attention if you develop any of these symptoms and/or symptoms of QT prolongation such as sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with ziftomenib.
The risk and/or severity of other side effects may also increase, including:
- nausea
- vomiting
- diarrhea
- fever
- infections
You may need additional monitoring if grapefruit or grapefruit juice are consumed during treatment with ziftomenib.
Talk to a healthcare provider if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
5 potential interactionsApplies to: 5 conditions, including Heart Failure, Liver Disease, Long QT Syndrome, Renal Dysfunction, and Electrolyte Abnormalities.
Electrolyte Abnormalities
Moderate:ziftomenib
Ziftomenib has a moderate potential interaction with Electrolyte Abnormalities.
Ziftomenib can cause QT (QTc) interval prolongation. Patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or who are taking medications known to prolong the QTc interval may require more frequent ECG monitoring. Perform an ECG and correct electrolyte abnormalities prior to starting treatment; do not initiate if QTcF is greater than 480 msec. Monitor ECG at least once weekly for the first 4 weeks of therapy, and at least monthly thereafter.
Heart Failure
Moderate:ziftomenib
Ziftomenib has a moderate potential interaction with Heart Failure.
Ziftomenib can cause QT (QTc) interval prolongation. Patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or who are taking medications known to prolong the QTc interval may require more frequent ECG monitoring. Perform an ECG and correct electrolyte abnormalities prior to starting treatment; do not initiate if QTcF is greater than 480 msec. Monitor ECG at least once weekly for the first 4 weeks of therapy, and at least monthly thereafter.
Liver Disease
Moderate:ziftomenib
Ziftomenib has a moderate potential interaction with Liver Disease.
The pharmacokinetics of ziftomenib have not been studied in patients with severe liver dysfunction. No adjustment recommended in patients with mild to moderate liver dysfunction.
Long QT Syndrome
Moderate:ziftomenib
Ziftomenib has a moderate potential interaction with Long QT Syndrome.
Ziftomenib can cause QT (QTc) interval prolongation. Patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or who are taking medications known to prolong the QTc interval may require more frequent ECG monitoring. Perform an ECG and correct electrolyte abnormalities prior to starting treatment; do not initiate if QTcF is greater than 480 msec. Monitor ECG at least once weekly for the first 4 weeks of therapy, and at least monthly thereafter.
Renal Dysfunction
Moderate:ziftomenib
Ziftomenib has a moderate potential interaction with Renal Dysfunction.
The pharmacokinetics of ziftomenib have not been studied in patients with severe renal dysfunction. No adjustment recommended in patients with mild to moderate renal dysfunction.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.